{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:54:57Z","timestamp":1794002097970,"version":"4.8.0"},"reference-count":71,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n            The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The National Comprehensive Cancer Network recommends that all patients with stage IVA and stage IVB urothelial carcinoma have molecular analysis that integrates at least\n            <jats:italic>FGFR3<\/jats:italic>\n            testing to help facilitate the selection of future therapeutic options. Sequencing of tumor-derived tissue is the mainstay to obtain this genomic testing, but as in other cancers, there has been extensive research into the integration of liquid biopsies in longitudinal management. Liquid biopsies broadly refer to the isolation of both cellular and noncellular tumor components including proteins and nucleic acids such as mRNA and circulating free DNA within a liquid sample. Although protein-based testing and testing of circulating tumor cells are options, the bulk of promising research in bladder cancer is investigating the role of plasma-based circulating tumor DNA (ctDNA). Currently, a universal consensus on optimal preanalytic and analytic approaches has not been fully defined, and the exact role that liquid biopsies should have in screening, diagnosis, prognostication, treatment selection, and monitoring is not yet known. Still, it can be expected that ctDNA testing will be a part of appropriate management of muscle-invasive bladder cancer and metastatic bladder cancer in the near future. In this review, the goal is to provide a practical overview of the current and future role of ctDNA in bladder cancer including ongoing trials.\n          <\/jats:p>","DOI":"10.1200\/edbk-25-471912","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T20:59:10Z","timestamp":1738270750000},"source":"Crossref","is-referenced-by-count":27,"title":["Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma"],"prefix":"10.1200","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-3421","authenticated-orcid":false,"given":"Joaquim","family":"Bellmunt","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute\/Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Russell","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett","family":"Szabados","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute (Barts Health NHS Trust), London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a P.","family":"Valderrama","sequence":"additional","affiliation":[{"name":"Hospital Virgen del Rocio, University Hospital Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Nadal","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_2_3_2","volume-title":"Cancer Stat Facts: Bladder Cancer","author":"NIH SEER Database","unstructured":"NIH SEER Database: Cancer Stat Facts: Bladder Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"key":"e_1_3_2_4_2","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala K","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, et al: Epidemiology of bladder cancer. Med Sci (Basel) 8:15, 2020","journal-title":"Med Sci (Basel)"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1215"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-023-00725-2"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.943253"},{"key":"e_1_3_2_9_2","unstructured":"Reference deleted"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-160075"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1008"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154"},{"key":"e_1_3_2_13_2","unstructured":"National Comprehensive Cancer Network: Bladder cancer (version 4.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.1026"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.2011"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030859"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2019.10.005"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2021.1963166"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2018.e00699"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9453"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvae079"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0392-0"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122280"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00568-z"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae198"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02052"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00660-y"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040859"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvac122"},{"key":"e_1_3_2_31_2","first-page":"484.e17","article-title":"BTA stat\u00ae, NMP22\u00ae BladderChek\u00ae, UBC\u00ae Rapid Test, and CancerCheck\u00ae UBC\u00ae rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study","volume":"41","author":"Ecke TH","year":"2023","unstructured":"Ecke TH, Meisl CJ, Schlomm T, et al: BTA stat\u00ae, NMP22\u00ae BladderChek\u00ae, UBC\u00ae Rapid Test, and CancerCheck\u00ae UBC\u00ae rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study. Urol Oncol Semin Orig Investig 41:484.e17-484.e26, 2023","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","unstructured":"Chaudhuri AA Pellini B Pejovic N et al: Emerging roles of urine-based tumor DNA analysis in bladder cancer management. JCO Precis Oncol 10.1200\/PO.20.00060","DOI":"10.1200\/PO.20.00060"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01555-0"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814374"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0303-5"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21327"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.597486"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70346"},{"key":"e_1_3_2_39_2","first-page":"326","article-title":"Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG","volume":"30","author":"Kashif Khan M","year":"2014","unstructured":"Kashif Khan M, Ahmed I, Raza SJ: Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG. Pak J Med Sci 30:326-330, 2014","journal-title":"Pak J Med Sci"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.01.007"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.657483"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512489"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.013"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2158"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS584"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.343"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4595"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4517"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16590"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401726"},{"key":"e_1_3_2_51_2","first-page":"183","article-title":"Perioperative use of ctDNA to guide treatment for urothelial carcinoma: The future is now","volume":"10","author":"Stewart TF","year":"2024","unstructured":"Stewart TF, Chalfin H, Simon N, et al: Perioperative use of ctDNA to guide treatment for urothelial carcinoma: The future is now. Bladder Cancer 10:183-198, 2024","journal-title":"Bladder Cancer"},{"issue":"00174","key":"e_1_3_2_52_2","first-page":"S2588","article-title":"Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer","volume":"24","author":"Sfakianos JP","year":"2024","unstructured":"Sfakianos JP, Basu A, Laliotis G, et al: Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer. Eur Urol Oncol S2588-9311(24)00174-3, 2024","journal-title":"Eur Urol Oncol"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03642-9"},{"key":"e_1_3_2_54_2","unstructured":"Reference deleted"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1860"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.09.011"},{"key":"e_1_3_2_57_2","article-title":"Disease-free survival and overall survival in patients with high-risk muscle-invasive bladder cancer who have persistent circulating tumor DNA-negative biomarker status post-cystectomy: IMvigor011 study surveillance analysis","author":"Bellmunt J","year":"2024","unstructured":"Bellmunt J, Gschwend J, Jensen J, et al: Disease-free survival and overall survival in patients with high-risk muscle-invasive bladder cancer who have persistent circulating tumor DNA-negative biomarker status post-cystectomy: IMvigor011 study surveillance analysis. SUO, 2024. https:\/\/www.urotoday.com\/conference-highlights\/suo-2024\/suo-2024-bladder-cancer\/156694-suo-2024-disease-free-survival-and-overall-survival-in-patients-with-high-risk-muscle-invasive-bladder-cancer-who-have-persistent-circulating-tumor-dna-negative-biomarker-status-post-cystectomy-imvigor011-study-surveillance-analysis.html","journal-title":"SUO"},{"key":"e_1_3_2_58_2","unstructured":"Reference deleted"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.007"},{"key":"e_1_3_2_60_2","unstructured":"Reference deleted"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2045"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00345-w"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20493-6"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113368"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0096-5"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01648-8"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.08.009"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1140"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3250"},{"key":"e_1_3_2_70_2","unstructured":"Rosa K: FDA Grants 2 Breakthrough Device Designations to Signatera MRD Test. 2021. https:\/\/www.onclive.com\/view\/fda-grants-2-breakthrough-device-designations-to-signatera-mrd-test"},{"key":"e_1_3_2_71_2","unstructured":"Ryan C: FDA Grants 501K Clearance to Bladder EpiCheck for Surveillance in NMIBC. 2023. https:\/\/www.onclive.com\/view\/fda-grants-501k-clearance-to-bladder-epicheck-for-surveillance-in-nmibc"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03091-7"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-471912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T20:59:15Z","timestamp":1738270755000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-471912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1200\/EDBK-25-471912"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-471912","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"e471912"}}